I-BET763

I-BET763 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, which include BRD2, BRD3, and BRD4. These proteins function as epigenetic readers that recognize acetylated lysine residues on histones and recruit transcriptional complexes to regulate gene expression. By binding to the bromodomain pockets, I-BET763 prevents the interaction between BET proteins and chromatin, thereby inhibiting the transcription of key oncogenes such as MYC. Preclinical research has investigated I-BET763 in the context of bladder and colon cancers, often evaluating its synergistic potential when combined with histone deacetylase (HDAC) inhibitors to suppress tumor cell growth and induce differentiation. Although primarily appearing in academic literature, it is part of the broader I-BET series of compounds originally developed by GSK.